Appili Therapeutics Inc. (APLI.TO)

CAD 0.04

(-12.5%)

EBITDA Summary of Appili Therapeutics Inc.

Appili Therapeutics Inc.'s latest annual EBITDA in 2023 was -2.09 Million CAD , down -3.49% from previous year.
Appili Therapeutics Inc.'s latest quarterly EBITDA in 2024 Q1 was -2.78 Million CAD , up 50.53% from previous quarter.
Appili Therapeutics Inc. reported an annual EBITDA of -8.19 Million CAD in 2022, up 67.08% from previous year.
Appili Therapeutics Inc. reported an annual EBITDA of -24.31 Million CAD in 2021, down -44.42% from previous year.
Appili Therapeutics Inc. reported a quarterly EBITDA of -2.41 Million CAD for 2023 Q4, down -1623.04% from previous quarter.
Appili Therapeutics Inc. reported a quarterly EBITDA of N/A for 2023 FY, down -3.49% from previous quarter.

Annual EBITDA Chart of Appili Therapeutics Inc. (2023 - 2016)

Historical Annual EBITDA of Appili Therapeutics Inc. (2023 - 2016)

Year	EBITDA	EBITDA Growth
2023	-2.09 Million CAD	-3.49%
2022	-8.19 Million CAD	67.08%
2021	-24.31 Million CAD	-44.42%
2020	-14.86 Million CAD	-202.25%
2019	-5.63 Million CAD	24.6%
2018	-4.93 Million CAD	-90.53%
2017	-3.79 Million CAD	0.24%
2016	-2.28 Million CAD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-2.78 Million CAD	50.53%
2023 Q4	-2.41 Million CAD	-1623.04%
2023 FY	- CAD	-3.49%
2023 Q3	158.46 Thousand CAD	138.44%
2023 Q2	-412.24 Thousand CAD	68.21%
2023 Q1	-1.29 Million CAD	41.28%
2022 Q1	-2 Million CAD	8.13%
2022 Q4	-2.2 Million CAD	6.66%
2022 FY	- CAD	67.08%
2022 Q3	-2.36 Million CAD	-103.32%
2022 Q2	-1.16 Million CAD	41.89%
2021 Q3	-2.98 Million CAD	72.98%
2021 FY	- CAD	-44.42%
2021 Q1	-7.32 Million CAD	-48.03%
2021 Q2	-11.04 Million CAD	-50.87%
2021 Q4	-2.17 Million CAD	26.96%
2020 FY	- CAD	-202.25%
2020 Q1	-2.59 Million CAD	-106.88%
2020 Q4	-4.94 Million CAD	-16.79%
2020 Q3	-4.23 Million CAD	-71.79%
2020 Q2	-2.46 Million CAD	5.07%
2019 Q3	-1.14 Million CAD	-3.0%
2019 Q2	-1.1 Million CAD	41.11%
2019 Q1	-1.88 Million CAD	-52.12%
2019 FY	- CAD	24.6%
2019 Q4	-1.25 Million CAD	-9.95%
2018 FY	- CAD	-90.53%
2018 Q4	-1.23 Million CAD	-8.01%
2018 Q1	-675.27 Thousand CAD	64.03%
2018 Q2	-1.29 Million CAD	-91.64%
2018 Q3	-1.14 Million CAD	11.5%
2017 FY	- CAD	0.24%
2017 Q4	-1.87 Million CAD	17.1%
2017 Q3	-2.26 Million CAD	0.0%
2016 FY	- CAD	0.0%

Peer EBITDA Comparison of Appili Therapeutics Inc.

Name	EBITDA	EBITDA Difference
Eupraxia Pharmaceuticals Inc.	-37.39 Million CAD	94.394%
Helix BioPharma Corp.	-9.38 Million CAD	77.672%
Microbix Biosystems Inc.	1.95 Million CAD	207.118%
Medicenna Therapeutics Corp.	-18.67 Million CAD	88.771%
Satellos Bioscience Inc.	-15.7 Million CAD	86.652%
Oncolytics Biotech Inc.	-33.71 Million CAD	93.781%
Sernova Corp.	-40.19 Million CAD	94.784%